Beroni Group, an Australia-based biopharmaceutical enterprise, said that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has signed a drug manufacture contract with Aurigene Pharmaceutical Services, India, a subsidiary of Dr. Reddy’s Laboratories.   This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed....